After its anni horribiles of 2021 and 2022, CureVac NV has started 2023 well, with its shares soaring on promising early-stage data for its second-generation mRNA vaccines and news that Sanofi veteran Alexander Zehnder will take over as CEO in the spring.
The German biotech has come fast out of the blocks this year, announcing positive data on 6 January from its ongoing Phase I clinical programs partnered with GSK plc in COVID-19 and seasonal flu, assessing both mRNA modified and unmodified (which CureVac had previously focused on) technology
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?